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Abstract
Cardiosphere-derived cells (CDCs) have been shown to reduce scar size and increase viable myocardium in human patients with mild/moderate
myocardial infarction. Studies in rodent models suggest that CDC therapy may confer therapeutic benefits in patients with non-ischaemic dilated
cardiomyopathy (DCM). We sought to determine the safety and efficacy of allogeneic CDC in a large animal (canine) model of spontaneous
DCM. Canine CDCs (cCDCs) were grown from a donor dog heart. Similar to human CDCs, cCDCs express CD105 and are slightly positive for c-
kit and CD90. Thirty million of allogeneic cCDCs was infused into the coronary vessels of Doberman pinscher dogs with spontaneous DCM.
Adverse events were closely monitored, and cardiac functions were measured by echocardiography. No adverse events occurred during and
after cell infusion. Histology on dog hearts (after natural death) revealed no sign of immune rejection from the transplanted cells.
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Introduction
Heart diseases remain the number one killer in western countries
[1]. Stem cell transplantation is a promising therapeutic strategy
for acute or chronic cardiomyopathy, considering current treat-
ments for human DCM usually involve intense drug regimen and/or
invasive implantable devices [2]. Small animal (rodent) studies are
widely adopted for initial proof of concept [3]. However, translation
to human trials necessitates large animal studies (e.g. pigs, dogs).
One dilemma is that many naturally occurring cardiomyopathies in
humans cannot be modelled effectively in the laboratory. Interest-
ingly, naturally occurring cardiomyopathy also affects the well-being
of domestic dogs. For instance, in Doberman pinschers, the DCM
appears to represent a major cause of death [4]. Dog and human
DCMs share significant clinical similarities including but not limited
to ascites, rhythm disruption, dyspnoea, syncope and sudden death
[5–7], which inspired us to ask the following: can we use Dober-
man pinschers with DCM as a spontaneously occurring, clinically
relevant large animal model of cardiomyopathy from which to
translate cell-based therapies for humans? The safety of adult stem
cell therapy for heart diseases has been well established in humans
[8]. Over the last 7 years, our laboratory has been studying CDCs
as a source to generate therapeutic cardiac progenitor cells for
ischaemic heart diseases. A recent clinical trial indicates that CDC
therapy benefits patients with mild-to-moderate myocardial infarc-
tion (MI) [9]. The regenerative potential of CDCs has also been
demonstrated in non-ischaemic cardiomyopathy [10, 11], and thus,
we hypothesize intracoronary CDC therapy can provide a safe and
effective intervention for DCM; in addition, successful implementa-
tion of this intervention in a canine model of DCM will provide
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valuable insight into our ability to apply this technique to treat
DCM in human beings.
Materials and methods
Derivation and culture of cCDCs
Canine CDCs were generated and expanded as described [3, 12] from
myocardial specimens of a healthy male beagle dog [8, 13]. Briefly, this
tissue was surgically collected from the right ventricle of a 2-year-old
canine beagle. An approximately 6 9 6 mm piece of myocardial tissue
was separated and washed with phosphate-buffered saline (PBS) (Life
Technologies, Carlsbad, CA., USA). The tissue sample was then cut into
smaller biopsy-sized pieces and washed three times with PBS, followed
by enzymatic digestion at 37°C in 5 mg/ml collagenase IV solution
(Sigma-Aldrich, St. Louis, MO, USA) for 5 min. Iscove’s modified Dul-
becco’s medium (IMDM; Life Technologies) containing 20% foetal bovine
serum (FBS; Corning, Corning, NY, USA) is then added to the sample to
inactivate the collagenase. After that, the tissue samples were further
minced into smaller tissue explants (~ 0.5 9 0.5 mm) before plating.
Approximately 50 pieces of tissue explants were then placed onto a fibro-
nectin-coated plate with approximately 1.5 cm between each explant and
covered with 2 ml of IMDM with 20% FBS overnight to aid the attach-
ment. The cultures were maintained in 25–30 ml IMDM with 20% FBS,
and media change was performed every other day. In about one week,
cells started to outgrow from the tissue explants. Once these outgrowth
cells are about 70–80% confluent, they were harvested by 5–10 min. of
incubation with TrypLE SelectTM (Life Technologies). The cells were then
seeded into an ultra-low-attachment flask (Corning) at a density of
100,000 cells/cm2 and cultured in IMDM with 10% FBS. Phase-bright
canine cardiospheres (CSps) started to form in 3–7 days. Canine CSps
were then collected from the low-attachment flasks and replated onto
fibronectin-coated surface to produce adherent cCDCs. cCDCs were cul-
tured in IMDM with 20% FBS media and passaged every 3–5 days.
Flow cytometry analysis
cCDCs were characterized by flow cytometry as described [13, 14]. Flow
cytometry was performed on cCDCs using a FACSCalibur and LSR II (BD)
and analysed using FLOWJO software (TreeStar, Carrboro, NC, USA). Cells
were incubated with antibodies against CD105 (ab156756; Abcam, Cam-
bridge, United Kingdom), CD90 (bd555595; BD Franklin Lakes, NJ, USA),
CD117 (c-kit, b5631; Abcam) for 60 min. Isotype-identical antibodies
served as negative controls.
Release testing for cCDCs before injection into
the dog patients
Gram stain testing (77730-1KT-F; Sigma-Aldrich) was used for sterility
testing for the final cell therapy product. Endotoxin testing was employed
(N283-06; Lonza, Basel, Switzerland) to ensure the cCDC product was
endotoxin-free. Cell viability and morphology were verified by trypan blue
before infusion. Catheter cell retention testing was performed to ensure
there was minimal cell loss between cell preparation and infusion into the
heart chamber.
Dog study protocol
All animal work is compliant with Institutional Animal Care and Usage
Committee at North Carolina State University. Once client-owned dogs
showed signs of DCM and a left ventricular shortening fraction of
<20% accompanied by LV dilatation, they were recruited from North
Carolina to participate in the study. After informed consent signed by
the dog owners, the dogs were randomized to either the CDC group or
the control group (no cell therapy, only standard care). Dogs placed
into the CDC group were given treatment 1 month after criteria were
met. This study plan consisted of taking measurements over a twelve-
month period and contained five dogs in the CDC group (age
1768  413 days) and three dogs in the control group (age
2366  531 days). Subject information can be found on Table 1.
Infusion of cCDCs
Following premedication with butorphanol (0.3 mg/kg intramuscularly)
and placement of an indwelling intravenous catheter, anaesthesia was
induced with midazolam (0.2 mg/kg IV) and etomidate (0.35 mg/kg IV).
Following routine endotracheal intubation, anaesthesia was maintained
with a continuous rate infusion of fentanyl (0.2 lg/kg/min) combined with
the lowest concentration of inhaled isoflurane needed to maintain a surgi-
cal plane of anaesthesia. Total anaesthetic duration for the procedures
averaged 50 min.
The dog was moved to a right lateral recumbent position in the cardiac
catheterization suite, and following aseptic preparation of the skin, a sur-
gical cut down was performed in the right femoral triangle, exposing the
right femoral artery. The artery was isolated and ligated distally with 3-0
silk suture, and a 5 Fr 9 7 cm Intradyn Braun vascular access sheath
was introduced using modified Seldinger technique. A 5-Fr. JR2.5 was
advanced into the aorta under fluoroscopic guidance, and the right coro-
nary ostium was engaged. A selective right coronary angiogram was per-
formed utilizing a hand injection of 5 cc of nonionic contrast media
Omnipaque (Y503; GE Healthcare, Little Chalfont, United Kingdom) to
confirm catheter placement. The catheter was then gently flushed with
5 ml of LRS (07-19-63-782; Baxter, Deerfield, IL, USA). 1 ml of PBS was
then flushed into the right coronary artery over 30 sec., followed by a
5 ml suspension of stem cells over 5 min., followed by another 2 ml of
PBS over an additional minute. The right Judkins catheter was then
removed. A 5-Fr. left Judkins catheter (JL3.5, 80 cm long) was then
advanced under fluoroscopic guidance to engage the left coronary
ostium, and a selective angiogram was performed with a hand injection
of 5 ml of Omnipaque to confirm the catheter position. In a fashion iden-
tical to the right coronary injection, the catheter was gently flushed with
5 ml of LRS. Two millilitres of PBS was then flushed into the left main
coronary artery over 30 sec., followed by a 10 ml suspension of stem
cells over 5 min., followed by another 4 ml of PBS over an additional
minute. Following the last injection of PBS, the catheter was removed,
the catheter sheath introducer was removed from the artery, and the
artery was double-ligated with 3-0 silk suture. The cut down incision was
closed routinely, and recovery from anaesthesia was uneventful.
Echocardiography measurement
Dogs were manually restrained, and all echocardiographic studies were
performed using a Phillips IE-33 echocardiographic system with
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simultaneous ECG. Standard imaging planes were obtained [15], and all
data were captured digitally for offline analysis at a digital workstation.
For this pilot safety study, simple M-mode measurements of left ventri-
cle end-diastolic and end-systolic dimensions (LVEDD and LVESD,
respectively) were obtained from the right parasternal short-axis image
at the level of the chordae according to recommendations set by the
American Society of Echocardiography [16]. The average of three mea-
surements from different sinus cardiac cycles was obtained. Fractional
shortening (FS) was calculated from the M-mode echocardiographic
images as (LVEDD—LVESD/LVEDD) 9 100%. As another indicator of
cardiac function, per cent wall thickness (%WT) was determined using
(end-systolic wall thickness - end-diastolic wall thickness)/end-diastolic
wall thickness 9 100% [17].
Histology
Hearts were collected from canine patients after natural death and
washed with PBS to remove excess biological fluids. Samples were
either frozen in OCT compound (Tissue-Tek) or placed in formalin and
later processed into paraffin blocks. Heart sections (5 lm thick) were
prepared from paraffin blocks. Haematoxylin and eosin stains were
performed on samples (MHS1; Sigma-Aldrich).
Fluorescence in situ hybridization (FISH)
To detect the male donor cells in the female recipient heart, we perform
Y-chromosome fluorescence in situ hybridization (FISH). Two hundred
nanograms from each sample was labelled using nick translation to
incorporate one of three fluorochromes, Spectrum Red/Orange/Green
dUTP (Vysis, Downers Grove, IL, USA). Typically, 25 ng of each of five
differentially labelled probes was pooled and precipitated in the
presence of 15 lg of sonicated genomic dog DNA as competitor. Chro-
mosome preparation, probe hybridization and post-hybridization washes
were performed as described previously [18, 19]. Chromosomes were
counterstained in 80 ng/ml 40, 6-diamidino-2-phenylindole (DAPI) and
mounted in antifade solution (Vectashield; Vector Laboratories, Burlin-
game, CA, USA). Images were acquired and processed using a multi-
colour FISH workstation comprising a fluorescence microscope
[Olympus BX61 (Shinjuku, Tokyo, Japan) with zero shift, narrowband
filters] CCD camera (CoolSnapHQ, Photometrics, Tuscon, AZ, USA) both
driven by dedicated software (SmartCapture 2.3.1 Digital Scientific,
Cambridge, UK). The digital image of each DAPI-stained metaphase
spread was processed using a high-pass spatial filter to reveal
enhanced DAPI bands. Clones were assigned to a chromosome region
according to the DAPI-banded nomenclature of Breen et al. [18, 19].
Statistical analysis
Results are presented as mean  S.D. unless specified otherwise. Com-
parisons between any two groups were performed using two-tailed
unpaired Student’s t-test. Comparisons among more than two groups were
performed using one-way ANOVA followed by post hoc Bonferroni correction.
Differences were considered statistically significant when P < 0.1.
Results
Generation of cCDCs
Using a three-stage ‘adhesion–suspension–adhesion’ culture process
(Fig. 1A), we derived CDCs from the myocardial tissues of a male
Table 1 Dog study design
Screening/Baseline Infusion Day 1 1 month 2 months 6 months 12 months
Study day Day 14 to Day 0 Day 0 Day 30 Day 60 Day 180 Day 360
Informed consent X
History/medication review X X X X X X
Adverse events assessment X X X X X X
Holter monitoring X X X X X
Vital sign X X X X X X
BNP X X X X X X
Serum troponin X X X
1 EDTA (purple) Tube X X X X X X
1 Sera (red) tube X X X X X X
vWF screening X
Echocardiography X X X X X
Intracoronary cell infusion X
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Beagle dog donor. Both phase-bright and stromal-like cells started to
outgrow from the canine heart tissue explants in a week after plating
onto fibronectin-coated surfaces. Those outgrowth cells become con-
fluent in ~2–3 weeks (Fig. 1B). When seeded on low-attachment sur-
faces (to discourage cell attachment), the outgrowth cells
spontaneously aggregate into three-dimensional canine cardio-
spheres (Fig. 1C). When replated onto a fibronectin-coated surface,
the cardiospheres dissociated into single cells which we termed CDC
(Fig. 1D). One biopsy-sized canine heart tissue can generate 50–200
million of passage 0 CDCs. Flow cytometry analysis (Fig. 1E) reveals
that cCDCs were positive for CD105, similar to human CDCs.
Intracoronary infusion of CDCs in Doberman
pinscher with DCM
Catheter testing performed before infusion verified a low amount of
cell loss through delivery, with >98% of cells passing through the
catheter. Canine CDCs were harvested by TrypLE Select, placed in
PBS with 100 U/ml heparin and stored at 4°C. Cell viability was >80%
for up to 5 hrs (Fig. 2A) under this storage condition. The cells were
infused with a regimen that was similarly applied in a previous human
trial (Fig. 2B) [8]. Coronary angiography (Fig. 2C) shows the
placement of the infusion catheter in the patient’s left main and right
coronary artery (RCA). The infusion dose in each artery was
described in Figure 2D.
Effects of CDC therapy on cardiac functions of
canines with DCM
Representative echocardiography image of a control and CDC-treated
animal at end-point shows the wall motions of the heart (Fig. 3A). As
an indicator of cardiac function, fractional shortening (FS%) contin-
ued to deteriorate in the control group (Fig. 3B, black lines). In con-
trast, CDC treatment robustly preserved FS% (Fig. 3B, red lines) with
a combination of responders and non-responders to the CDC treat-
ment. Treatment effects were calculated as the change in FS% from
the baseline to end-point (Fig. 3C). A similar trend was found in per
cent wall thickness, which was used as an another indicator of cardiac
function (Fig. 3D and E). Intragroup analysis indicated decreases in
FS% and WT% in the control group (Fig. 4A and B), while CDC treat-
ment protected FS% and WT% (Fig. 4C and D). Left ventricular diam-
eter diastolic (LVDd) and left ventricular diameter systolic (LVDs)
were measured at baseline and end-point (Fig. 5). In general, the
changes in LV dimensions were indistinguishable between the two
Fig. 1 Derivation and culture of canine CDCs. (A) Schematic diagram showing the derivation of canine CDC a of Beagle dog. (B) Outgrowth cells
from plated myocardial tissues. (C) Cardiosphere formation in suspension culture. (D) CDCs dissociated from cardiospheres. (E) Expressions of
CD105, CD90, ckit by flow cytometry in canine CDCs. Scale bars = 50 lm in all images.
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groups. The control and CDC treatment groups had similar brain
natriuretic peptide (BNP) (Fig. 6A) and cardiac troponin I (cTnI)
(Fig. 6B) levels at baseline and end-point. This was measured to
ensure the cell infusion did not exacerbate myocardial damage.
Allogeneic CDC infusion does not engraft or
cause immune rejection in the heart
Autopsy on hearts from CDC-treated, and control, dogs were sliced
for gross inspection (Fig. 7A). Survival rates were similar for each
group (Fig. 7B). No tumour formation was detected. Representative
FISH staining (Fig. 7C) revealed no male donor cells in the female
recipient heart. Haematoxylin and eosin staining shows the lack of
concentration of cell nuclei (Fig. 7D), when compared to control heart
(Fig. 7E), or a healthy (normal) heart (Fig. 7F), suggesting the allo-
geneic CDC infusion did not elicit an immune response from the
heart. This was consistent from our previous findings in rat and
human allogeneic CDC transplantations.
Discussion
The last decade witnessed a burst of cell therapy trials for ischaemic
cardiomyopathy. For the last 7 years, our laboratory has been study-
ing CDCs and recently showed the regenerative potential of CDCs in a
mouse model of induced DCM [20]. Results from a recent clinical
trial also indicated that infusion of autologous CDCs in patients with
mild-to-moderate myocardial infarction reduced scar but increased
viable tissue [8]. A phase II clinical trial is ongoing to test the regener-
ative potential of allogeneic CDCs in patients with recent MI [21].
Domestic dogs suffer from a variety of spontaneously occurring
heart diseases. In Doberman pinschers, the autosomal dominant
inheritance pattern of DCM described in some families is similar to
that of DCM in humans [7, 22]. Expected survival time in Dobermans
is strikingly short, and current treatment is symptomatic and pallia-
tive. This provides us with an excellent opportunity to use the Dober-
man pinscher as a naturally occurring model of DCM for CDC
therapy.
In the present study, we demonstrate that cCDCs can be derived
from adult dog hearts and that they are phenotypically similar to
human and rodent CDCs (Fig. 1). Similar to human CDCs [20], cCDCs
are positive for CD105 but have low expressions of CD90 and ckit.
Recent studies have shown that ckit expression is irrelevant to the
overall therapeutic benefit of CDCs, while CD90 expression undermi-
nes the regenerative potential of CDCs [23, 24]. Allogeneic CDCs have
proven to be safe in both rat models of myocardial infarction [25] and
in an ongoing human trial [23], and the results of using allogeneic
cCDCs derived from a Beagle dog donor for treating Doberman pin-
scher dogs with DCM appear to confirm this finding in dogs as well.
Before the cell infusion procedure, lot release criteria testing was
performed to ensure the cell therapy product was free of bacterial
agents, mycoplasma and endotoxin. In addition, we performed a
storage stability assay to check for how long can the cells remained
viable while being stored in the infusion solution at 4°C. Our data
indicated that cell viability was >80% up to 5 hrs after collection
Fig. 2 Cell infusion procedure. (A) Viability of CDCs stored at 4°C. (B) Intracoronary cell infusion design. (C) Coronary angiography showing catheter
placement in left main and RCA. (D) Schematic diagram showing the infusion dose.
ª 2017 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
1507
J. Cell. Mol. Med. Vol 21, No 8, 2017
(Fig. 2A), which provided abundant time for the myocardial distribu-
tion and infiltration of viable stem cells, as well as maintained secre-
tion of growth factors for treatment. In addition, any normal delay in
patient preparation for infusion would have little adverse effects on
cell viability in clinical.
As DCM induces widespread myocardial dysfunction, it is essen-
tial to distribute large number of therapeutic stem cells globally. We
designed a two-vessel infusion protocol to cover the entire heart: 20
million cells into the left main artery and 10 million cells into the RCA
(Fig. 2C and D). To ensure a fast and safe treatment, we devised a
‘wash–cell–wash’ infusion plan that allowed for an infusion to take
less than 20 min. as well as ensuring no excessive cell accumulation
in the vessel (Fig. 2B). The infusion scheme used here has also been
applied to human patients. Previous studies have investigated the car-
diac benefits of stem cells through intramyocardial injection in rodent
models successfully [26, 27], but this method is invasive and limited
to local areas of myocardium. Catheter-based intra-arterial infusion of
stem cell therapies delivered at the time of myocardial reperfusion is
emerging as a promising candidate to improve LV dysfunction in por-
cine model of MI [28, 29]. In our present study, we applied intracoro-
nary infusion by two vessels which involved left main artery and RCA,
which we hope ensured the global distribution of therapeutic stem
cells. In addition, delivering cells by ‘wash–cell–wash’ method may
reduce the retention of stem cells in the coronary vessel, presumably
promoting beneficial effects in remote areas of the heart.
DCM is characterized by progressive ventricular dilatation and
contractile dysfunction. While there was no significant change in
LVDd and LVDs from baseline to end-point for both control and CDC
groups (Fig. 5), our results revealed a consistent protection of FS%
and WT% by the CDC therapy (Fig. 3). CDC therapy may also mitigate
the progression of ventricular enlargement and deterioration of
myocardial systolic function (Fig. 4). According to previous studies
[10, 30], CDCs could promote cardiomyocyte proliferation and pro-
tect myocytes from antioxidant, antifibrotic and anti-inflammatory
injury. Cardiac stretch indicators (NT-BNP) and cell injury markers
(cTNI) showed no significant difference between the control and CDC
groups (Fig. 6), suggesting cell infusion had no benefit, but also did
not exacerbate myocardial stretch or damage as measured by these
biomarkers.
Compared to autologous cell therapy, allogeneic cell products
offer several benefits, namely the short time required for produc-
tion and the low cost per dosage. In addition, patient-specific tissue
harvesting and cell processing may introduce possible variations in
cell potency related to patient age and disease [31]. One major
Fig. 3 Effects of CDC therapy on cardiac function. (A) Representative echocardiography images showing control and CDC-treated dogs at end-point.
(B) Fractional shortening (FS%) comparison between control and CDC groups. (C) Treatment effects as gauged by change in FS%. (D) WT% com-
parison between control and CDC groups. (E) Treatment effects as gauged by change in WT%. End-point was consistent for all dogs and taken at
the 3-month time-point.
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concern of allogeneic therapy is the potential risk of host immune
response. Previous studies have investigated the safety of allo-
geneic CDC transplantation in rats and pigs with myocardial
infarction [25, 28], but the safety and efficacy of allogeneic CDCs
in DCM models have not been explored. Here, we tested the speci-
fic hypothesis that allogenic CDCs could not engraft permanently in
Fig. 4 Intragroup analysis of FS% and WT
% in control and CDC-treated animals. (A)
FS% at baseline and end-point for the
dogs in the control group. (B) WT% at
baseline and end-point for the dogs in the
control group. (C) FS% at baseline and
end-point for the dogs in the CDC group.
(B) WT% at baseline and end-point for
the dogs in the CDC group. End-point was
consistent for all dogs and taken at the
3-month time-point.
Fig. 5 Left ventricle dimensions. (A) Comparison of LVDd change over the time between control and CDC groups. (B) LVDd at baseline and end-point for
the dogs in the control group (C) LVDd at baseline and end-point for the dogs in the CDC group. (D) Comparison of LVDs change over the time between
control and CDC groups. (E) LVDs at baseline and end-point for the dogs in the control group. (F) LVDs at baseline and end-point for the dogs in the con-
trol group. End-point was consistent for all dogs and taken at the 3-month time-point.
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transplanted myocardium, but could still exert therapeutic effects.
No immune cell infiltration was observed in the recipient heart
(Fig. 7), which attested the safety of allogeneic cell therapy in the
DCM model [25].It has been reported that there were no circulating
antidonor antibodies after allogeneic CDC transplantation in rats
with MI [25]. In addition, the amount and volume of CDC therapy
are relatively small compared to those in blood transfusion, and it
has also been shown that injected CDCs do not persist beyond
3 weeks in the heart [25]. Thus, the absence of such sensitization
may explain why allogeneic cells could be survived in recipient.
These results open the door to many different allogeneic treatments
that can be tested in the future.
Fig. 6 Cardiac failure and injury markers. (A) Comparison of serum BNP levels in control and CDC groups before and after infusion. (B) Comparison
of serum cTNI levels in control and CDC groups before and after infusion. End-point was consistent for all dogs and taken at the 3-month time-point.
Fig. 7 Heart histology. (A) Transversal
section of CDC-treated canine heart (B)
Survival data comparing control (n = 3)
and CDC-treated (n = 5) groups. (C)
Representative FISH stain showing lack of
engraftment of infused male allogeneic
cCDC in native female Doberman heart.
(D) Haematoxylin and eosin staining
showing no infiltration of cell nuclei from
immune response, indicating allogeneic
CDC infusion did not stimulate rejection.
(E) A representative section from control
animal heart. (F) A representative section
from healthy Doberman heart. Scale
bars = 5 and 100 lm
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In summary, we derived cCDCs from adult dog hearts and showed
their safety in an allogeneic canine DCM model.
Limitations
There are some limitations to this study. The use of client-owned ani-
mals that matched criteria for study limited the total number of ani-
mals that could be used. This limitation in sample size prevented our
ability to find true significance in many factors that were trending
towards significance. Another limitation is that only one cell donor
was used for all cell recipients.
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